CPHI 2025: ‘handprint’ metric bridges pharma sustainability and economic value
The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.
Drug Manufacturers
Chiesi and Aliada sign licence deal for enzyme replacement therapies
Novartis opens California site for RLT manufacturing
Abzena and Mabqi partner for drug development solution
CPHI 2025: time for European biopharma to double down on innovation
Lifecore and PolyPeptide link for US peptide manufacturing
AstraZeneca doubles Lokelma output with $445m Texas plant expansion
BIOSECURE returns to US pharma agenda with 2.0 update
